(NASDAQ: OCGN) Ocugen's forecast annual revenue growth rate of 337.08% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Ocugen's revenue in 2026 is $5,370,000.On average, 7 Wall Street analysts forecast OCGN's revenue for 2026 to be $981,309,792, with the lowest OCGN revenue forecast at $0, and the highest OCGN revenue forecast at $1,967,616,706. On average, 4 Wall Street analysts forecast OCGN's revenue for 2027 to be $41,597,915,717, with the lowest OCGN revenue forecast at $31,103,959,954, and the highest OCGN revenue forecast at $52,319,865,162.
In 2028, OCGN is forecast to generate $150,163,509,850 in revenue, with the lowest revenue forecast at $93,330,619,069 and the highest revenue forecast at $202,680,136,682.